Milrinone in Congenital Diaphragmatic Hernia

Infants with congenital diaphragmatic hernia (CDH) usually have pulmonary hypoplasia and persistent pulmonary hypertension of the newborn (PPHN) leading to hypoxemic respiratory failure (HRF). Pulmonary hypertension associated with CDH is frequently resistant to conventional pulmonary vasodilator therapy including inhaled nitric oxide (iNO). Increased pulmonary vascular resistance (PVR) can lead to right ventricular overload and dysfunction. In patients with CDH, left ventricular dysfunction, either caused by right ventricular overload or a relative underdevelopment of the left ventricle, is associated with poor prognosis. Milrinone is an intravenous inotrope and lusitrope (enhances cardiac systolic contraction and diastolic relaxation respectively) with pulmonary vasodilator properties and has been shown anecdotally to improve oxygenation in PPHN. Milrinone is commonly used during the management of CDH although no randomized trials have been performed to test its efficacy. Thirty percent of infants with CDH in the Children's Hospital Neonatal Database (CHND) and 22% of late-preterm and term infants with CDH in the Pediatrix database received milrinone. In the recently published VICI trial, 84% of patients with CDH received a vasoactive medication. In the current pilot trial, neonates with an antenatal or postnatal diagnosis of CDH will be randomized to receive milrinone or placebo to establish safety of this medication in CDH and test its efficacy in improving oxygenation.

Study Overview

• Status: Recruiting
• Conditions: Persistent Pulmonary Hypertension of the Newborn; Congenital Diaphragmatic Hernia; Hypoxemic Respiratory Failure; Pulmonary Hypoplasia
• Intervention / Treatment: Drug: Milrinone; Drug: Placebo (5% Dextrose)

Detailed Description

This is a pilot trial to determine if milrinone infusion in neonates ≥ 36 weeks' postmenstrual age (PMA) at birth with CDH would lead to an increase in PaO2 with a corresponding decrease in OI by itself or in conjunction with other pulmonary vasodilators such as iNO at 24 h post-infusion.

• Study Type: Interventional
• Enrollment (Estimated): 66
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Abhik Das, PhD; Phone Number: 301-230-4640
• Study Contact Backup: Name: Satyan Lakshminrusimha, M.D.; Phone Number: 916-734-5178; Email: slakshmi@ucdavis.edu

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • Recruiting
      • University of Alabama at Birmingham
      • Contact: Waldemar A Carlo, MD
  • California
    • Palo Alto, California, United States, 94304
      • Recruiting
      • Stanford University
      • Contact: Krisa P Van Meurs, MD
  • Georgia
    • Atlanta, Georgia, United States, 30303
      • Recruiting
      • Emory University
      • Contact: David P Carlton, MD
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Recruiting
      • University of Iowa
      • Contact: Edward F Bell, MD
  • Missouri
    • Kansas City, Missouri, United States, 64108
      • Recruiting
      • Children's Mercy
      • Contact: John M Daniel, MD
  • New Mexico
    • Albuquerque, New Mexico, United States, 87131
      • Recruiting
      • University of New Mexico
      • Contact: Kristi L Watterberg, MD
  • New York
    • New York, New York, United States, 10032
      • Recruiting
      • Columbia University
      • Contact: Rakesh Sahni, MD
    • Rochester, New York, United States, 14642
      • Recruiting
      • University of Rochester
      • Contact: Carl T D'Angio, MD
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Recruiting
      • Duke University
      • Contact: Michael Cotten, MD
    • Durham, North Carolina, United States, 27709
      • Active, not recruiting
      • RTI International
  • Ohio
    • Cincinnati, Ohio, United States, 45267
      • Recruiting
      • Cincinnati Children's Medical Center
      • Contact: Brenda Poindexter, MD
    • Cleveland, Ohio, United States, 44106
      • Recruiting
      • Case Western Reserve University, Rainbow Babies and Children's Hospital
      • Contact: Michele C Walsh, MD MS
    • Columbus, Ohio, United States, 43205
      • Recruiting
      • Research Institute at Nationwide Children's Hospital
      • Contact: Pablo Sanchez
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Recruiting
      • University of Pennsylvania
      • Contact: Barbara Schmidt, MD
  • Rhode Island
    • Providence, Rhode Island, United States, 02905
      • Recruiting
      • Brown University, Women & Infants Hospital of Rhode Island
      • Contact: Abbot R Laptook, MD
  • Texas
    • Dallas, Texas, United States, 75235
      • Recruiting
      • University of Texas Southwestern Medical Center at Dallas
      • Contact: Myra Wyckoff, MD
    • Houston, Texas, United States, 77030
      • Recruiting
      • University of Texas Health Science Center at Houston
      • Contact: Kathleen A Kennedy, MD MPH
  • Utah
    • Salt Lake City, Utah, United States, 84108
      • Recruiting
      • University of Utah
      • Contact: Bradley Yoder, MD
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Recruiting
      • Children's Hospital of Wisconsin
      • Contact: Ganesh Konduri, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 second to 1 week (Child)
• Accepts Healthy Volunteers: No

Description

Eligibility criteria:

Infants are eligible if they meet all of the following criteria:

• ≥ 36 0/7 weeks PMA by best obstetric estimate AND birth weight of ≥ 2000g
• postnatal age ≤7 days (168 hours of age)
• invasive mechanical ventilation (defined as ventilation with an endotracheal tube) and
• one arterial blood gas with an OI ≥ 10 (after tracheal tube obstruction and other easily resolvable mechanical causes for increased OI are ruled out) on the most recent arterial blood gas within 12 hours prior to the time of randomization.
• if an arterial blood gas is not available at the time of randomization, a preductal OSI of ≥ 5 can be used as an inclusion criterion instead of OI ≥ 10; (the OSI should be based on the most recent preductal pulse oximetry recording and must be within 12 hours of randomization)
• postnatal blood gas with PCO2 ≤ 80 mmHg (arterial, capillary or venous blood gas) on the most recent blood gas sample obtained within 12 hours prior to randomization Note: Criteria (iv) to (vi) must be met at the most recent analysis within 12 hours prior to randomization.

Exclusion Criteria:

Infants are ineligible if they meet any of the following criteria:

• known hypertrophic cardiomyopathy

  • Note 1: infants of diabetic mothers with asymmetric septal hypertrophy can be included as long as there is no evidence of obstruction to left ventricular outflow tract on echocardiogram,
  • Note 2: infants with other acyanotic congenital heart disease (CHD) and CDH may be included in the study and will be a predetermined subgroup for analysis)
• cyanotic CHD - transposition of great arteries (TGA), total anomalous pulmonary venous return (TAPVR), partial anomalous pulmonary venous return (PAPVR), truncus arteriosus (TA), tetralogy of Fallot (TOF), single ventricle physiology - hypoplastic left heart syndrome (HLHS), tricuspid atresia, critical pulmonic stenosis or atresia etc.,
• enrolled in conflicting clinical trials (such as a randomized controlled blinded trial of another pulmonary vasodilator therapy); Note: mothers enrolled in fetal tracheal occlusion studies such as FETO may be enrolled if permitted by investigators of the fetal tracheal occlusion study; [FETO refers to fetoscopic endoluminal tracheal occlusion and involves occlusion of fetal trachea with a balloon device at mid-gestation and subsequent removal in later gestation]

• infants with bilateral CDH

  o Note 3: infants with anterior and central defects are included in the study

• associated abnormalities of the trachea or esophagus (trachea-esophageal fistula, esophageal atresia, laryngeal web, tracheal agenesis)
• renal dysfunction (with serum creatinine > 2 mg/dL not due to maternal factors) or severe oligohydramnios associated with renal dysfunction at randomization; renal dysfunction may be secondary to renal anomalies or medical conditions such as acute tubular necrosis
• severe systemic hypotension (mean blood pressure < 35 mm Hg for at least 2 h with a vasoactive inotrope score of > 30)
• decision is made to provide comfort/ palliative care and not full treatment

• Intracranial bleed (including the following findings on the cranial ultrasound)

  • Cerebral parenchymal hemorrhage
  • Blood/echodensity in the ventricle with distension of the ventricle
  • Periventricular hemorrhagic infarction
  • Posterior fossa hemorrhage
  • Cerebellar hemorrhage
• persistent thrombocytopenia (platelet count < 80,000/mm3) despite blood product administration on the most recent blood draw prior to randomization
• coagulopathy (PT INR > 1.7) despite blood product administration on the most recent blood draw (if checked - there is no reason to check PT for the purpose of this study)
• aneuploidy associated with short life span (such as trisomy 13 or 18) will not be included in the study (infants with trisomy 21 can be included in the study)
• elevated arterial, venous or capillary PCO2 > 80 mmHg in spite of maximal ventilator support (including high frequency ventilation) on the most recent blood gas obtained within 12 hours prior to randomization
• use of milrinone infusion prior to randomization (the use of other inhaled pulmonary vasodilators such as iNO, inhaled epoprosternol, inhaled PGE1 and oral such as endothelin receptor antagonists is permitted - Note: it is unlikely to be on oral pulmonary vasodilators early in the course of CDH)
• ongoing therapy with parenteral (intravenous or subcutaneous) pulmonary vasodilators such as IV/SQ prostacyclin analogs (Epoprostenol - Flolan or Treprostinil - Remodulin or PGE1 - Alprostadil) or IV phosphodiesterase 5 inhibitors (sildenafil - Revatio) at the time of randomization. In addition, initiation of therapy with these two classes of parenteral medications during the first 24 hours of study drug initiation is not permitted and will be considered a protocol deviation. The risk of systemic hypotension is high during the first 24 hours of study-drug (milrinone) infusion and hence parenteral administration of other pulmonary vasodilators is avoided to minimize risk of hypotension.
• Subjects already on ECMO or patients who are being actively considered for ECMO by the neonatal or surgical team
• attending (neonatal, critical care or surgical) refusal for participation in the trial (including concern about presence of hemodynamic instability)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Milrinone; Milrinone infusion at 0.33µg/kg/min. The dose of the study drug will be increased to 0.66 µg/kg/min if oxygenation index (OI) remains ≥ 10 without any evidence of hypotension (as defined by the protocol) two hours after initiation of study drug. Infusion will be continued until the OI decreases to < 7. The maximum duration of study drug infusion is 72 hours.	Drug: Milrinone; The study intervention is an intravenous infusion of milrinone or placebo; Other Names: Primacor; Milrinone Lactate Injection
Placebo Comparator: 5% dextrose (D5W); An equivalent volume of 5% dextrose (D5W) will be used for infants randomized to the placebo arm.	Drug: Placebo (5% Dextrose); The study intervention is an intravenous infusion of milrinone or placebo; Other Names: D5W

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Oxygenation Response	The primary outcome is the oxygenation response, as determined by change in OI (or OSI) at 24 h after initiation of study drug. The last OI (or OSI) prior to initiation of ECMO or death will be used for analysis if infant requires ECMO or dies within 24 h of initiation of the study drug.	24 h after initiation of study drug

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Oxygenation Response at 48 and 72 h	Oxygenation index at 48 and 72 h (or OI at the time of initiation of ECMO or immediately prior to death, for infants placed on ECMO or died before these time points)	48 and 72 h after initiation of study drug
Changes in estimated systolic pulmonary arterial pressure on echocardiogram	Changes in echocardiogram to assess pulmonary arterial pressure (as defined by protocol) between pre-study drug echocardiogram and echocardiogram obtained between 24 and 72 h after starting the study drug. The outcome will be available only for those infants who have a pre-study drug echocardiogram and a second echocardiogram between 24 and 72 hours after initiation of study drug performed for clinical reasons.	Prior to initiation of study drug to between 24 and 72 hours after initiation of study drug
Vasoactive Inotrope Score and Systemic Blood Pressure	Vasoactive Inotrope Score is a quantitative assessment of the degree of therapeutic support required by the patient to maintain adequate perfusion and/or blood pressure.	72 hours after initiation of study drug
Area Under the Curve for Inspired Oxygen	Area under the curve for inspired oxygen after initiation of the study drug (inspired oxygen and ventilator data from 4 time points per day - every 6 hours will be recorded to calculate area under the curve)	After initiation of the study drug at 4 time points per day - every 6 hours x 72 hours or discontinuation of study drug (whichever comes first)
Oxygenation Response to Additional Inotropes or Pulmonary Vasodilators	If subsequent to the study drug, any additional inotrope or pulmonary vasodilator is used (such as iNO), we will evaluate the oxygenation response to these agents. If inotropes or vasodilators were used prior to the initiation of study drug, similar values will be recorded. The OI and PaO2/ FiO2 ratio prior to at least 30 min after initiation of the inotrope / vasodilator are recorded. The change in OI and PaO2/ FiO2 ratio in response to these agents is evaluated as a continuous variable and arbitrarily classified into responders, partial responders and non-responders	Through 24 h post study drug initiation
Supplemental Continuous Oxygen	The use of supplemental oxygen at 28 d will be used to calculate the incidence of chronic lung disease. Chronic lung disease severity will be classified similar to the BPD classification in preterm infants at > 32 week gestation.	28 days and 56 days postnatal age (or discharge whichever comes first)
Survival to discharge without ECMO		Measured by no ECMO at time of hospital discharge or at the time the infant reaches 120 days of life and remains in the hospital, whichever comes earlier
Clinical status (Pulmonary and Nutritional)	Clinical status - pulmonary (use of supplemental oxygen or respiratory medications - diuretics, methylxanthines, steroids, inhaled or nebulized steroids or bronchodilators) and nutritional (weight, length, head circumference, use of anti-reflux medications)	All clinical status measures (as defined by protocol) will be obtained just prior to the infants discharge from the hospital and again at 12 months of age.
Feasibility and sample size calculation to Perform a Definitive Trial (primary outcome - improvement in survival without ECMO		From initial recruitment: 16 patients enrolled per month to complete the trial in 4 years
Feasibility to perform a definitive trial (incidence of systemic hypotension)		From initial recruitment: 16 patients enrolled per month to complete the trial in 4 years
Feasibility to perform a definitive trial (incidence of intracranial bleeding)		From initial recruitment: 16 patients enrolled per month to complete the trial in 4 years
Feasibility to perform a definitive trial (incidence of arrhythmias)		From initial recruitment: 16 patients enrolled per month to complete the trial in 4 years
Adjusted Oxygen Response		24 h after initiation of study drug

Collaborators and Investigators

• Sponsor: NICHD Neonatal Research Network
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Investigators: Principal Investigator: Satyan Lakshminrusimha, M.D., University of California, Davis

Publications and helpful links

General Publications

• Lakshminrusimha S, Keszler M, Kirpalani H, Van Meurs K, Chess P, Ambalavanan N, Yoder B, Fraga MV, Hedrick H, Lally KP, Nelin L, Cotten M, Klein J, Guilford S, Williams A, Chaudhary A, Gantz M, Gabrio J, Chowdhury D, Zaterka-Baxter K, Das A, Higgins RD. Milrinone in congenital diaphragmatic hernia - a randomized pilot trial: study protocol, review of literature and survey of current practices. Matern Health Neonatol Perinatol. 2017 Nov 27;3:27. doi: 10.1186/s40748-017-0066-9. eCollection 2017.

Study record dates

Study Major Dates

• Study Start (Actual): August 22, 2017
• Primary Completion (Estimated): March 31, 2024
• Study Completion (Estimated): March 31, 2025

Study Registration Dates

• First Submitted: October 14, 2016
• First Submitted That Met QC Criteria: October 28, 2016
• First Posted (Estimated): November 1, 2016

Study Record Updates

• Last Update Posted (Estimated): March 1, 2024
• Last Update Submitted That Met QC Criteria: February 28, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: PPHN; CDH; HRF
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Congenital Abnormalities; Infant, Newborn, Diseases; Pathological Conditions, Anatomical; Internal Hernia; Hypertension; Hernia; Respiratory Insufficiency; Hypertension, Pulmonary; Persistent Fetal Circulation Syndrome; Hernias, Diaphragmatic, Congenital; Hernia, Diaphragmatic; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Enzyme Inhibitors; Platelet Aggregation Inhibitors; Protective Agents; Cardiotonic Agents; Phosphodiesterase Inhibitors; Phosphodiesterase 3 Inhibitors; Milrinone
• Other Study ID Numbers: NICHD-NRN-0057; UG1HD034216 (U.S. NIH Grant/Contract); UG1HD027904 (U.S. NIH Grant/Contract); UG1HD021364 (U.S. NIH Grant/Contract); UG1HD027853 (U.S. NIH Grant/Contract); UG1HD040689 (U.S. NIH Grant/Contract); UG1HD040492 (U.S. NIH Grant/Contract); UG1HD027851 (U.S. NIH Grant/Contract); UG1HD087229 (U.S. NIH Grant/Contract); UG1HD053109 (U.S. NIH Grant/Contract); UG1HD068278 (U.S. NIH Grant/Contract); UG1HD068244 (U.S. NIH Grant/Contract); UG1HD068263 (U.S. NIH Grant/Contract); UG1HD027880 (U.S. NIH Grant/Contract); UG1HD053089 (U.S. NIH Grant/Contract); UG1HD087226 (U.S. NIH Grant/Contract); U10HD036790 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Per NIH Data Sharing Plan

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No